BCL2 and hematologic disorder: A switch of the apoptotic dependency from BCL-2 to other anti-apoptotic proteins, such as MCL-1 or BCL-XL, or even a general reduction of apoptotic priming has been described in venetoclax resistance in several hematological malignancies [10,11,12].